Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited
Your view on BOT.AX
Overview
What the company does, where it operates, and who runs it.
About Botanix Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howie McKibbon
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howie McKibbon
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Botanix Pharmaceuticals Limited, and the rating behind it. BOT.AX last traded at AUD 0.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Botanix Pharmaceuticals Limited. Starting points for Botanix Pharmaceuticals Limited: EPS -AUD 0.05, beta 0.86 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Botanix Pharmaceuticals Limited. Trailing twelve-month EPS for Botanix Pharmaceuticals Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Botanix Pharmaceuticals Limited valued side by side against its closest peers. Botanix Pharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Botanix Pharmaceuticals Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Botanix Pharmaceuticals Limited executives and directors. Shares of Botanix Pharmaceuticals Limited have traded between AUD 0.02 and AUD 0.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Botanix Pharmaceuticals Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Botanix Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Botanix Pharmaceuticals Limited. Coverage tracks Botanix Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.